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In humans, connexins (Cxs) and pannexins (Panxs) are the building blocks of
hemichannels. These proteins are frequently altered in neoplastic cells and have
traditionally been considered as tumor suppressors. Alteration of Cxs and Panxs in cancer
cells can be due to genetic, epigenetic and post-transcriptional/post-translational events.
Activated hemichannels mediate the diffusional membrane transport of ions and small
signaling molecules. In the last decade hemichannels have been shown to participate
in diverse cell processes including the modulation of cell proliferation and survival.
However, their possible role in tumor growth and expansion remains largely unexplored.
Herein, we hypothesize about the possible role of hemichannels in carcinogenesis and
tumor progression. To support this theory, we summarize the evidence regarding the
involvement of hemichannels in cell proliferation and migration, as well as their possible
role in the anti-tumor immune responses. In addition, we discuss the evidence linking
hemichannels with cancer in diverse models and comment on the current technical
limitations for their study.
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OVERVIEW OF MAMMALIAN HEMICHANNELS AND
METHODOLOGICAL CONSIDERATIONS
Multicellular organisms have evolved with sophisticated routes
for cell-to-cell communication. Such interactions are multidi-
mensional (e.g., they occur between different types of cells, in
diverse spatial orientation/direction, environmental conditions
and time frames) and create signaling circuits within tissues, ulti-
mately allowing for a more efficient use of resources and coordi-
nation of responses. In addition to a myriad of membrane recep-
tors, channels and transporters, mammalian cells are equipped
with relatively large, low-resistance proteinaceous conduits to
transmit signaling molecules such as ions (e.g., Na+ and K+),
second messengers (e.g., Ca2+ and phosphatidylinositol 1,4,5-
trisphosphate [IP3]), nucleotides (e.g., cAMP, ADP, and ATP) and
metabolites (e.g., glucose, adenosine, glutamate and glutathione)
across electrochemical gradients. Such structures correspond to
aqueous pores formed by hexamerization of subunits of two topo-
logically related vertebrate protein families commonly referred to
as “gap junction-type proteins”: connexins (Cxs) and pannex-
ins (Panxs). In humans, there are 21 different Cxs genes with a
wide genomic distribution and 3 genes encoding Panxs located
in chromosomes 11 (Panx1 and 3) and 22 (Panx2) (Baranova
et al., 2004; Söhl and Willecke, 2004). Cxs and Panxs show no
sequence homology and there is no evidence supporting for-
mation of mixed Cxs/Panxs based channels. Alternative splicing
variants and pseudogenes for some of these transcripts have been
described in humans, but their biological relevance is uncertain.
Paradoxically (and for historical reasons), when such channels are
recognized as single structures they are termed “hemichannels” or
“connexons,” although they really are whole, functional cell mem-
brane channels allowing the passage of relatively small solutes up
to ∼1.2 kDa. When two of such channels/connexons, each from
one adjacent cell, converge to areas of intercellular membrane
contact and serially dock allowing for continuous communi-
cation of cytosols, they are termed intercellular gap junction
channels (Sáez et al., 2003). In a conservative view, hemichan-
nels have been considered to remain preferentially closed in
resting conditions and to serve mainly as structural precursors
of gap junction channels through lateral diffusion and cluster-
ing after membrane insertion (Gaietta et al., 2002). However,
independent site-specific and cytoskeleton-dependent membrane
targeting routes for hemichannels, either to areas of cell-cell junc-
tions or to unopposed membrane clusters, have been described
(Shaw et al., 2007). The relevance of Cx-based hemichannels
and intercellular channels in physiology has become evident by
the demonstration of disease phenotypes associated with Cxs
mutations affecting protein conformation, turnover and channels
function (reviewed in Schalper et al., 2009; Pfenniger et al., 2011).
Diverse structural and functional factors limit the study Cx
and Panx hemichannels and intercellular gap junction chan-
nels in biological systems. The first major challenge is clear
discrimination between hemichannels and intercellular chan-
nels. Hemichannels and intercellular channels formed by the
same Cx or Panx usually coexist in cells and show overlapping
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permeability to ions/molecules and a similar (not highly specific)
pharmacological sensitivity (Retamal et al., 2007a; Giaume and
Theis, 2010; Fiori et al., 2012). In addition, hemichannels and
gap junction channels formed by most studied Cxs and Panxs
share a common amino acid sequence, secondary structure and
transcriptional/post-transcriptional regulation (Sáez et al., 2003;
Riquelme et al., 2013a). Therefore, molecular methods or con-
ventional antibody-based detection are usually limited to study
the levels, location, stoichiometry and participation of each chan-
nel type in any given response. In addition, the difficulties to
recapitulate in vitro the complex multi-cellular/multidimensional
tissue conditions have limited a clear dissection of the relative
contribution of each channel type to various physiological and
pathological processes. To overcome some of the aforementioned
limitations, mimetic peptides and antibodies targeting specific
regions at the extracellular (docking) domains have been used
to allow structure-specific recognition/blockade of hemichannels
(recently reviewed in Riquelme et al., 2013a).
The second major problem is discriminating between the con-
tribution of Cx and Panx-based channels to any given response.
Channels and hemichannels formed by Cxs or Panxs have func-
tional, pharmacological similarities and overlapping expression
patterns. In particular, Panxs have been shown to have glycosy-
lation sites on the extracellular loop and a high glycosylation level
could preclude the serial docking of Panx hemichannels (Boassa
et al., 2008; Peñuela et al., 2013). This led to the notion that
Panxs form exclusively hemichannels and not intercellular gap
junction channels (Sosinsky et al., 2011). However, recent studies
confirmed the early findings by Bruzzone et al. (2003) show-
ing that at least Panx1 and 3 can form functional intercellular
gap junction channels with independent properties (Sahu et al.,
2014). Future studies exploring diverse cell/tissues and various
experimental conditions will be required to support and extend
this concept. Further details on the transcriptional regulation of
Cx and Panx genes, structural and functional characteristics of
Cx- and Panx-based channels, post-translational modifications,
pharmacological properties and methodological considerations
are discussed in comprehensive reviews published elsewhere by
our group and by others (Goodenough and Paul, 2003; Sáez
et al., 2003, 2010; Baranova et al., 2004; Söhl and Willecke, 2004;
Panchin, 2005; Schalper et al., 2008b; Giaume and Theis, 2010;
Kar et al., 2012; D’Hondt et al., 2013; Peñuela et al., 2013).
The aforementioned methodological limitations for the study
of hemichannels both in vitro and in vivo and the possible “con-
tamination” of results by additional yet anonymous transmem-
brane routes have pointed out possible flaws in the interpretation
of correlative dyes/molecules uptake or release and electrophysi-
ological studies demonstrating hemichannel existence and func-
tions (Spray et al., 2006). However, the evidence on intercellular
gap junction channels also largely relies on comparable correlative
expression/function studies using dye transfer and electrophysi-
ological experiments combined with pharmacological blockade.
Direct intercellular communication pathways different from gap
junction channels termed intercellular nanotubes have recently
been described (reviewed in Sherer, 2013) and should be con-
sidered in the interpretation of gap junction studies. In addition,
the intercellular transfer of regulatory molecules in specialized
small bi-layered membranous vesicles termed exosomes (or ecto-
somes) could also contribute to some of the responses attributed
exclusively to gap junction channels, particularly in the central
nervous system (Kalani et al., 2014), immune system (Hwang,
2013) and cancer cells (Azmi et al., 2013). Channel-independent
functions of Cxs and Panxs have also been well described and add
difficulty to the interpretation of results (Vinken et al., 2012).
Most studies evaluating the functions and properties of inter-
cellular channels in various conditions have not simultaneously
addressed possible changes in hemichannel functions. Thus, a
comparable degree of skepticism should exist on the notion of
the exclusive involvement of intercellular channels in many stud-
ies correlating Cx and Panx expression with certain responses
or phenotypes. Finally, visual localization of hemichannels and
gap junction channels has been performed largely using antibod-
ies, some of which have not been thoroughly validated regarding
their specificity, optimal titration/dynamic range, reproducibility
and stability over time. The lack of specificity and reproducibil-
ity of commercial and in-house established antibodies represents
a common flaw in biomedical research (Bordeaux et al., 2010).
In this regard, personal experience working in the gap junction
field, as well as reports by other authors have highlighted possi-
ble limitations and conflicting results using presumably specific
antibodies (Yahalom et al., 1991; Coppen et al., 2002; Shurman
et al., 2005; Brisset et al., 2009; Cone et al., 2013). Moreover,
the relative contribution of technical error and biological vari-
ations in antibody-based results (e.g., diverse protein folding,
sample fixation, antigen retrieval, blocking solutions, alternative
transcripts, and posttranslational modifications) are not easy to
discern. Careful validation of reagents and, more important, sys-
tematic reporting of antibodies lacking specificity/reproducibility
could help to overcome this complex scenario.
GAP JUNCTION PROTEINS AND CANCER
After the seminal work by Drs. Werner Loewenstein and
Yoshinobu Kanno showing impaired intercellular electrical cou-
pling in chemically-induced and xenografted rat hepatocarci-
nomas (Loewenstein and Kanno, 1966, 1967), the role of gap
junctions in cancer cells has been a subject of interest for the
last five decades. A considerable number of articles on this sub-
ject have been published and the literature has been periodically
reviewed (see Loewenstein, 1980; Trosko et al., 1983; Kanno,
1985; Yamasaki, 1990; Mesnil and Yamasaki, 1993; Mesnil et al.,
1995; Trosko and Ruch, 1998; Mesnil, 2002; Naus, 2002; Mesnil
et al., 2005; Cronier et al., 2009; Kandouz and Batist, 2010; Naus
and Laird, 2010). In general, cancer cells from various types
and after diverse experimental challenges have been shown to
have lower expression of their native gap junction proteins than
non-tumor samples. Also, highly proliferative tumor cells show
atypical (e.g., predominantly cytoplasmic) expression of these
proteins and impaired gap junctional intercellular communica-
tion. Restoration of the gap junction-type proteins and/or inter-
cellular communication is frequently associated with reduced cell
proliferation, which led to the broad concept that Cxs and Panxs
were tumor suppressors. However, emerging data on the role
of these proteins in tumor cell migration and metastasis have
challenged this paradigm and pointed to situations in which
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these proteins could actually favor cancer progression (Cronier
et al., 2009; Kandouz and Batist, 2010; Naus and Laird, 2010).
Unfortunately, little of the knowledge on this subject has been
translated to cancer medicine and the possible role of hemichan-
nels in carcinogenesis and tumor progression remains largely
unexplored. Previous studies on hemichannels have used trans-
formed cell models. However, key experiments addressing the
functions and impact of hemichannels in cancer cells have not
yet been communicated and include: (i) detailed characteriza-
tion of the presence and relative abundance of hemichannels in
cancer cells; (ii) evaluation of hemichannel-mediated molecule
uptake/release in tumor cells as compared to non-tumor cells;
(iii) functional consequences of hemichannels activation and
blockade in tumor cells and neoplasms and (iv) prognostic and
predictive value of hemichannels expression/activation in human
malignancies.
In this article, we hypothesize that functional hemichannels
can be present in tumor cells (at least of some tumor subtypes or
tumor cell subpopulations) and they could alter tumor cell pro-
liferation and disease progression through the transmembrane
exchange of signaling solutes such as nucleotides and Ca2+. To
test this theory, we review the literature regarding the involve-
ment of hemichannels in cancer-related processes such as cell
proliferation/death and cell migration; and revisit some of the gap
junction/cancer studies from a “hemichannel-centric” perspec-
tive. We also speculate on the possible role of hemichannels in
cancer progression and as a clinically useful biomarker.
REGULATION OF Cx AND Panx EXPRESSION IN HUMAN
CANCER
Most tumor cells harbor genetic and epigenetic defects that
lead to altered protein expression and signaling. The presence
of gene amplification, rearrangements and acquisition of the
so-called “driver” activating mutations are hallmarks of many
clinically actionable oncogenes including HER2, EGFR, KRAS,
c-KIT, and ALK. In addition, malignant cells frequently down-
regulate or silence transcripts associated with anti-tumor char-
acteristics (e.g., tumor suppressor genes) such as P53, RB, and
PTEN. Silencing of such alleles can occur by gene deletion, inac-
tivating mutations or by epigenetic alterations (e.g., promoter
hypermethylation and histonemodifications). Finally, tumor cells
can also alter the expression of transcripts post-transcriptionally
by microRNA-mediated silencing or using the more recently
described long non-coding RNAs (lncRNAs) system (Hauptman
and Glavac, 2013).
Cxs and Panxs have been frequently shown to display altered
expression in human tumors and cancer cell lines. Diverse studies
have addressed the underlying mechanisms and they are summa-
rized in Table 1. Of note, recent efforts in exome/genome-wide
sequencing using massive parallel sequencing strategies of diverse
human malignancies such as the TCGA (The Cancer Genome
Atlas) have been completed and to date, mutations in Cxs and
Panxs have not emerged as frequent events. Moreover, naturally
occurring mutations have been reported in Cx genes and are fre-
quently associated with complex disease phenotypes (Schalper
et al., 2009). To our knowledge, no mutations in human Panx
genes have been communicated. Taken together, this suggests
that regulation of gap junction-type proteins in cancer cells
could be more frequently associated with epigenetic and post-
transcriptional events, as suggested in pioneering experiments
characterizingmRNA transcripts using substractive hybridization
methods in cultured normal and tumor breast epithelial cells (Lee
et al., 1991).
Cx AND Panx GENE MUTATIONS IN HUMAN CANCER
Early efforts looking for Cx mutations in cancer specimens
found that 4 of 7 primary human hepatic angiosarcomas car-
ried a proline-to-serine substitution in codon 319 of the Cx37
gene (Saito et al., 2000). The same genetic variant was found
in DNA extracts from adjacent non-tumor tissue, suggest-
ing that it corresponded to a germline mutation or a single
nucleotide polymorphism. The amino acid 319 is located in
the cytoplasmic tail of the protein that contains diverse regula-
tory motifs. Of note, Cx37 has been shown to form functional
hemichannels (Wong et al., 2006) and its expression reduced
the proliferation of cultured rat insulinoma cells (Burt et al.,
2008). In follow-up studies it was shown that introduction
of Cx37 mutations that abrogate both the intercellular chan-
nel and hemichannel functions (T154A and C61A-C65A) failed
to suppress the proliferation (Good et al., 2011, 2012). The
inablity of the mutant protein to mimic the effect of the wild
type Cx37 in cell proliferation indicates that the passage of
molecules through Cx37-based channels is required to influence
cell growth/survival. In addition, association between the C1019T
polymorphism of the Cx37 gene, gastric adenocarcinomas and H.
pylori infection was identified in a retrospective Chinese cohort
(Jing et al., 2012).
Another study looking for Cx mutations in sporadic colorec-
tal cancers found 2 frameshift Cx43 mutations in 3 of 6 studied
tumors (a single nucleotide deletion A311V in 2 samples and
a single nucleotide insertion I358N in 1 tumor) (Dubina et al.,
2002). No alterations in Cx32 gene were identified. The Cx43 vari-
ants were mapped to the carboxy-terminal tail of the peptide and
were not detected in DNA extracts from peripheral blood sam-
ples, confirming their somatic nature. However, such mutations
have not been mechanistically characterized or further reported
in larger tumor series.
Using a high-resolution array-based CGH platform to screen
human hepatocellular carcinomas, deletions in the region encod-
ing the Cx40.1 gene were identified (Zender et al., 2008). In sup-
port of a tumorigenic effect of this variant, an in vivo, xenograft-
based RNAi screen showed that Cx40.1 downregulation using
shRNA elicited a prominent acceleration of tumor growth. Little
is known about the properties of human Cx40.1. For instance, it
is expressed in the human heart (Söhl andWillecke, 2004), but its
channel forming capacity remains to be proven.
Deletions of an 817 kb area at 6q14-21 containing the Cx62
gene were found in DNA extracts from 21 of 55 human pro-
static adenocarcinomas using a high-resolution single nucleotide
polymorphism array (Liu et al., 2007). However, the levels of
Cx62 mRNA from the ONCOMINE database were compara-
ble between tumor samples and normal controls, suggesting
that another transcript located in this deleted segment such as
MAP3K7 might have tumor suppressive actions.
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Table 1 | Possible mechanisms responsible for reduced expression of connexins in human cancers and cell lines.
Protein Tumor Alteration
Cx26 Squamous cell carcinoma oral cavity Missense heterozygous single nucleotide mutation F142L (Rednam et al., 2011)
Transitional carcinoma cell lines Histone demethylation (Li et al., 2013)
Small cell carcinoma (SCLC) and SCLC cell lines Promoter hypermethylation (Chen et al., 2005)
Invasive breast carcinoma (IBC) and IBC cell lines Promoter hypermethylation (Tan et al., 2002)
Cx30 Colorectal carcinoma (CRC) and CRC cell lines Promoter hypermethylation (Sirnes et al., 2011)
Cx32 Renal cell carcinoma cell lines Promoter hypermethylation (Hirai et al., 2003)
Gastric carcinoma Promoter hypermethylation (Schalper et al., 2014, this report)
Cx36 Colorectal carcinoma (CRC) and CRC cell lines Promoter hypermethylation (Sirnes et al., 2011)
Cx37 Colorectal carcinoma Promoter hypermethylation (Sirnes et al., 2011)
Hepatic angiosarcoma High frequency of codon 319 polymorphism in vinyl chloride-related tumors
(Saito et al., 2000)
Cx40.1 Hepatocellular carcinoma Deletion (Zender et al., 2008)
Cx43 Colorectal carcinoma Single nucleotide deletion A311V, Single nucleotide insertion I358N (Dubina
et al., 2002)
Non-small cell lung carcinoma Promoter hypermethylation (Jinn and Inase, 2010)
Prostate carcinoma cell lines Histone deacetylation (Hernandez et al., 2006), miR-20a expression is inversely
correlated with Cx43 expression (Li et al., 2012a,b)
Glioblastoma multiforme cell line miR-221/222 targets Cx43 mRNA, decreasing its expression (Hao et al., 2012)
Nasopharyngeal carcinoma (NPC) and NPC cell line miR-218 targets Cx43 mRNA and is downregulated in NPC (Alajez et al., 2011)
Cx45 Colorectal cancer cell lines Promoter hypermethylation (Sirnes et al., 2011)
Cx62 Prostate carcinoma 6q14-21 deletion (Liu et al., 2007)
Aggressive oral squamous cell carcinomas are predominantly
associated with alcohol and tobacco use and are extremely rare in
children. Interestingly, the case of a 6-year old girl was reported
with psoriasiform dermatitis and sensorineural hearing loss that
presented with a high grade, 3.3 cm palatal and nasal squamous
cell carcinoma (Rednam et al., 2011). Due to the clinical findings
the patient was screened and the single nucleotide Cx26 mutation
F142L was found. Although there was no demonstration of causal
relationship between the tumor and the Cx26 variant, other
Cx26 mutations associated with excessive keratinocyte prolifer-
ation and syndromic hearing loss have been shown to produce
hemichannels with increased function and altered permeability
(Sánchez et al., 2010; Mese et al., 2011).
EPIGENETIC REGULATION OF EXPRESSION OF Cxs AND Panxs IN
CANCER
Epigenetic regulation of Cxs is a well-described process (reviewed
in Vinken et al., 2009; Oyamada et al., 2013). Reduction in the
expression of diverse Cxs with concomitant promoter hyperme-
thylation has been shown in multiple human neoplasms and
tumor cell lines. Downregulation of Cx32 gene expression by
promoter hypermethylation was shown using bisulphite mod-
ified DNA-based PCR and a restriction enzyme-based assay
in HK-2 and Caki-2 human renal cell carcinoma cells (Hirai
et al., 2003). Treatment of cells with the demethylating agent
5-Aza-2′-Deoxycytidine restored Cx32 expression, confirming
that Cx32 expression was suppressed. Similarly, downregulation
of Cx43 in nasopharyngeal carcinoma CNE-1 cells was found
to be associated with GJA1 (Cx43) gene hypermethylation (Yi
et al., 2007). A high frequency of Cx30, Cx36, and Cx37 promoter
hypermethylation was also detected in colorectal carcinoma sam-
ples, as well as in Cx30, Cx36, and Cx45 in colon cancer cell
lines (Sirnes et al., 2011). However, correlation between reduced
transcript levels and the presence of promoter methylation was
found only for Cx45. A more recent study identified Cx45 pro-
moter hypermethylation in 33% of 485 colorectal carcinomas and
a positive association with the actionable oncogenic BRAF exon
15 mutation (e.g., V600E) was noted (Ahmed et al., 2011).
Low Cx43 protein levels in human non-small cell carcino-
mas were associated with Cx43 CpG island promoter methylation
and with heavy tobacco use (Jinn and Inase, 2010). Strikingly,
the presence of Cx43 promoter hypermethylation in the non-
tumor peritumoral lung tissue, but not in the tumor tissue
proper, was significantly associated with lymph node positivity
in non-small cell cancer patients (Chen et al., 2003). The bio-
logical determinants of this association are not clear. Reduced
Cx26 protein and mRNA levels in a variety of lung carcinomas
(including small-cell neuroendocrine carcinomas) and cell lines
was also correlated with promoter hypermethylation and reverted
by 5-Aza-2′-Deoxycytidine (Chen et al., 2005). Cx26 promoter
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hypermethylation was also found in 11 of 20 human invasive
breast carcinomas and in cell lines (Tan et al., 2002). However,
the absence of Cx26 expression in human squamous esophageal
carcinoma cells was not correlated with the presence of Cx26 pro-
moter hypermethylation, suggesting the presence of a different
silencing mechanism (Loncarek et al., 2003). Using methyla-
tion specific PCR, we found Cx32 promoter hypermethylation
in 4 of 9 frozen samples from human gastric adenocarcinomas
(Schalper et al., unpublished observation, Figure 1). The 246 bp
methylation-specific band was detected exclusively in the tumor
and not in non-tumor areas of the samples (Figure 1A). However,
we found no clear relationship between the presence of Cx32
promoter hypermethylation and Cx32 protein levels as detected
by immunohistochemistry (Figures 1B,C). Taken together, these
findings suggest that although more frequent in cancer tissues,
promoter hypermethylation in Cxs genes is not unequivocally
related with reduced/absent protein.
To our knowledge, regulation of Panx genes by epigenetic con-
trol has not been reported. Using the NIH PROSCAN webtool
(http://www-bimas.cit.nih.gov/molbio/proscan/), we evaluated a
1000 bp region upstream of the initiation codon of the human
Panx1 gene. We identified a 434 bp region with diverse tran-
scription factor binding motifs and a significant probability of
being a promoter region (Promoter score = 88.86; Promoter
cutoff = 53.00). In the same genomic region and using the
EMBL-EBI Cpgplot tool (https://www.ebi.ac.uk/Tools/seqstats/
emboss_cpgplot/) we detected a 554 bp region with >50% C/G
FIGURE 1 | Methylation of Cx32 promoter region in human gastric
adenocarcinomas. (A) Agarose gel showing the results from methylation
specific PCR of sodium bisulphite-modified DNA extracted from 9 frozen
gastric adenocarcinomas (1T-9T) and non-tumor tissue from the same
subjects (1N-9N). In 4 cases, a 246 bp band corresponding to the
methylated sequence in the Cx32 promoter region was identified. C(+) =
Positive control sample of methylated DNA; C(−) = Negative control lacking
template DNA. (B,C) Microphotographs showing Cx32 immunostaining in
morphologically normal human liver (B) and non-tumor (N)/tumor (T)
interface from one gastric adenocarcinoma sample (C). Liver was used as
positive control and showed homogenous and intense membranous-like
staining. Cx32 immunoreactivity was also detected in the normal foveolar
gastric epithelium (N) and in malignant epithelial carcinoma cells (T). The
previously reported (Sánchez et al., 2009) monoclonal anti-Cx32 antibody
clone 72F (dilution 1:1500, overnight incubation) was used to stain frozen
sections. Preparations were then counterstained with hematoxilin. Bar
= 100μm.
nucleotides, consistent with a CpG island. The latter suggests that
human Panx1 has a CpG nucleotide-rich promoter region and
could be modulated by hypermethylation.
Few events associated with histone modifications have been
shown to affect Cx26 and Cx43 genes in human neoplasms. Li
and collaborators (Li et al., 2013) recently found an inverse rela-
tionship between Cx26 and JARID1B (also known as KDM5B)
histone demethylase protein levels in transitional cancer cell
lines and advanced human bladder tumors. Overexpression of
JARID1B was associated with reduced Cx26 protein in HT1376
and T24 cells, indicating that this demethylase represses Cx26
expression.
In androgen dependent (LNCaP) and androgen-independent
human prostate cancer cell lines (DU145 and PC3), treatment
with the histone deacetylase inhibitor Trichostatin A prominently
increased Cx43 mRNA and protein expression. The intercellular
transfer of the fluorescent dye Lucifer yellow was also increased by
Trichostatin A, indicating increased gap junction mediated inter-
cellular communication (Hernandez et al., 2006). Similar find-
ings were observed in cultured non-malignant human peritoneal
mesothelial cells (Ogawa et al., 2005).
POST-TRANSCRIPTIONAL REGULATION OF EXPRESSION OF Cxs AND
Panxs IN CANCER
Post-transcriptional modulation by small non-coding RNAs of
Cx genes has also been reported in human tumors. Li et al.
(2012a,b) found an inverse relationship between miR-20a and
Cx43 protein and mRNA expression in human prostate tumors
and cell lines. In this model, downregulation of miR-20a caused
a 4-fold increase in Cx43 expression and reduced the cell
proliferation. Using a luciferase reporter assay, the miR-20a
antagomir increased the luciferase activity using the wild type
Cx43 sequence, but was ineffective with Cx43 mutated at the
miR-20a binding site at the 3′UTR region. The latter demon-
strates that Cx43 is a direct target of miR-20a. Using a similar
approach, miR-221/222 was shown to bind Cx43 mRNA, reduce
Cx43 expression and promote cell growth and invasion in the
human glioblastoma multiforme cell line U251 (Hao et al., 2012).
Finally, transfection of miR-218 in nasopharyngeal carcinoma
cells reduced Cx43 expression and was associated with increased
apoptosis. Moreover, miR-218 transfection reduced the tumor
growth after intramuscular implantation of C666-1 cells in SCID
mice (Alajez et al., 2011). Although likely to occur, regulation of
Cxs expression by lncRNAs has not been reported yet. In addition
and to our knowledge, modulation of Panxs by non-coding RNAs
has not been communicated.
HEMICHANNELS IN CELL PROLIFERATION AND TUMOR
PROGRESSION
The cellular consequences of altered hemichannel functions
are believed to be mediated mainly by defective trans-
membrane transport of signaling molecules passing through
them, leading to altered activation of intracellular path-
ways and autocrine/paracrine signals. Key molecules associ-
ated with cell proliferation/survival and shown to perme-
ate activated hemichannels include NAD+ (nicotinamide ade-
nine dinucleotide), cADPR (cyclic ADP-ribose), ATP, Ca2+,
www.frontiersin.org June 2014 | Volume 5 | Article 237 | 5
Schalper et al. Hemichannels in cancer
FIGURE 2 | Possible role of hemichannels in tumor growth and
progression. Diagram showing the paracrine interactions mediated by the
passage of nucleotides and Ca2+ through hemichannels between tumor cells
(T), lymphocytes (L), and stromal cells (S). The image in the upper left corner
depicts the tumor microenvironment components with intimate relationship
between the tumor and non-tumor cells. The expanded inset on the right
represents a magnification of one tumor area and indicates the signaling
circuits associated with NAD+ (green text and arrows), ATP (red text and
arrows), and Ca2+ (blue text and arrows). The image also shows the
presence and possible interactions between connexin (Cx) and pannexin
(Panx) hemichannels, ectonucleotidases, purinergic receptors, and adenosine
receptors. Arrows with dashed lines indicate a positive/stimulatory effect,
arrows with continuous lines indicate a negative/inhibitory effect; and curved
lines indicate (enzymatic) metabolic activity. ADO, adenosine; AMP,
adenosine monophosphate; ATP, adenosine triphosphate; cADPR, cyclic
adenosine diphosphate-ribose; [Ca2+]i, free intracellular Ca2+ concentration;
NAD+, nicotinamide adenine dinucleotide; P2X7, P2X purinoreceptor 7. See
text for detailed explanation of the biological consequences of each pathway.
IP3, glutathione, and prostaglandin E2 (Wang et al., 2013a,b).
However, additional, yet unidentified, relatively small-sized
solutes could also mediate autocrine/paracrine effect in cells. In
particular, the nucleotides NAD+ and ATP have been directly
involved in hemichannel mediated cell proliferation (of non-
tumor cells) by increasing the intracellular Ca2+ levels. Therefore,
the exchange of these nucleotides and Ca2+ through hemichan-
nels will be the main focus of this section. Also, the transmem-
brane passage of nucleotides constitutes a unique feeder system
for extracellular nucleotidases that have a prominent role in
the anti-tumor immune responses (see below). In addition, the
increasingly recognized paracrine signaling between tumor and
stromal cells that may occur through hemichannels could also
support their involvement in tumor growth and cancer progres-
sion. A summary of the possible functions of hemichannels in
cancer biology is presented in Figure 2.
HEMICHANNELS AND NAD+ METABOLISM
The cellular NAD+ homeostasis is tightly regulated in all organ-
isms and contributes to the maintenance of the energetic balance,
intracellular redox potential and signal transduction. Tumor cells
undergo metabolic adaptations to support growth and survival,
including a pronounced shift from oxidative phosphorylation
toward more NAD+ and lactate production through aerobic
glycolysis, a phenomenon known as the Warburg effect (Chiarugi
et al., 2012). The net cellular NAD+ content is the result from its
synthesis by various enzymatic cascades involving niacin (vitamin
B3), tryptophan, aspartic acid and reutilization of intracellular
nicotinamide-related compounds, as well as NAD+ degradation
through enzymatic hydrolysis, ribosylation and deacetylation.
CD38 is the major mammalian NAD+ glycohydrolase and ADP-
ribosyl cyclase, thus directly participating in NAD+ metabolism
and production of second messengers (Chiarugi et al., 2012).
However, the catalytic domain of CD38 is located in the extra-
cellular domain, apart from its cognate intracellular substrate.
The first experimental evidence for the involvement of Cx43
hemichannels in transmembrane NAD+ transport came from
studies using cultured NIH3T3 fibroblasts, HeLa cells and prote-
oliposomes (Bruzzone et al., 2001). In these models, NAD+ efflux
required (and was paralleled by) Cx43 expression. Moreover, the
NAD+ release was increased by lowering the extracellular Ca2+
concentration and prominently blocked by beta-glycyrrhetinic
acid, La3+ and a Cx43 monoclonal antibody, thus implicat-
ing Cx43 hemichannels (Bruzzone et al., 2001). Shortly after,
the same group convincingly demonstrated the involvement of
Cx43 hemichannels in the [Ca2+]i-dependent, cADPR-induced
cell proliferation in co-cultured mouse NIH/373 fibroblasts with
or without CD38 expression (Franco et al., 2001; De Flora
et al., 2004). In this model, the efflux of NAD+ through acti-
vated hemichannels allowed the interaction of this intracellularly
produced dinucleotide with the extracellular catalytic segment
of CD38, giving a mechanistic response to this topographical
paradox. After its production by CD38-mediated NAD+ ribo-
sylation, the ubiquitous second messenger cADPR can re-enter
the cells to induce IP3-pathway independent-/ryanodine receptor
induced Ca2+ transients and ultimately mediate cell cycling and
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proliferation. Later studies by another research group extended
these observations and showed that cADPR re-uptake is medi-
ated by Cx43 hemichannels through bidirectional NAD+ extru-
sion/cADPR import upon FCγ receptor stimulation in cultured
murine J774A.1 macrophages (Song et al., 2011) (Figure 2, green
colored arrows and text).
Although CD38 is expressed in various mammalian tissues
including brain, prostate and muscle, it is most prominently
found in lymphoid/blood cells (Deaglio et al., 2008). CD38 is
frequently upregulated and has been indicated as a prominent
oncogenic and adverse prognostic factor in hematologic malig-
nancies including multiple myeloma and chronic lymphocytic
leukemia. Moreover, humanized monoclonal antibodies target-
ing CD38 (e.g., daratumumab, MOR03087, and SAR650984)
are under evaluation in early phase clinical trials to treat
patients with advanced hematological B-cell malignancies (www.
clinicaltrials.gov; trial identifiers NCT01615029, NCT00574288,
NCT01749969, NCT01084252 and NCT01421186). As an
integral component of the CD38-Cx43-cADPR axis and
NAD+ degradation pathway, it is tempting to speculate that
expression of Cx43 in neoplastic cells could serve as a prognos-
tic/predictive biomarker for such compounds and modulation of
Cx43 hemichannels may itself represent a novel anti-tumor
therapeutic target, especially in CD38 expressing B cell
malignancies.
Cx43 was shown to be expressed in isolated human B cells from
tonsil and peripheral blood and Cx-based channels participate
in immunoglobulin production and B cell maturation (Oviedo-
Orta et al., 2000, 2001). In addition, Cx43 defective knockout
mice have lower IgM-positive B cells than their wild type litter-
mates and the defect is more pronounced in the homozygous
than in the heterozygous animal, supporting a gene-dosage effect
(Montecino-Rodriguez and Dorshkind, 2001). Although some
authors have ascribed the functional effects of lymphocyte Cx43
to their participation in the pool of intercellular channels located
at the cell-cell contacts between activated immune cells (e.g., “the
immunological synapse”), the involvement of hemichannels in
these processes has not been excluded. This is particularly rele-
vant in immune cells that are expected to spend a considerable
part of their lifespan detached from other cells. In this regard,
the reduction in immunoglobulin levels observed byOviedo-Orta
and collaborators in primary human lymphocytes was triggered
by traditional Cx-channel blockers and by a Cx43 mimetic pep-
tide corresponding to the second extracellular loop (e.g., Gap27)
(Oviedo-Orta et al., 2001), known to inhibit Cx43 hemichannels
(Evans et al., 2006; Wang et al., 2012). Notably, additional short
peptides corresponding to the intracellular domains of Cx43 (e.g.,
Gap18 and Gap20) were ineffective in this model.
More recently, Cx43 was shown to be required for activation
and migration of cultured murine B cells (Machtaler et al., 2011).
In this study, B cell responses were independent of intercellu-
lar gap junction channels and immunofluorescence experiments
of Cx43 in the murine B lymphoma cell lines WEHI 231 and
A20, and in primary murine B splenocytes, showed a predomi-
nant homogenous membranous distribution. The latter indicates
a lack of preferential clustering/enrichment of Cx43 in areas
of cell-cell contact. A similar diffuse membranous Cx43/CD38
co-localization staining pattern was observed in cultured J774A.1
macrophages (Song et al., 2011).
Surprisingly few studies have explored the expression of Cxs in
native human lymphoid tissues and human lymphoid neoplasms.
For instance, Cx43 was detected in germinal centers of fresh sam-
ples from human tonsil and spleen (Krenacs et al., 1997). Of note,
Cx43 protein andmRNAwere predominantly located in cells with
irregular shape and co-expressing CD21 and CD35, consistent
with follicular dendritic cells. Only scarce, more rounded cells
with lymphocyte appearance and of undefined lineage were found
to carry the Cx43 transcript in this study.
Aiming to characterize Cx43 expression in native human
lymphoid tissues and lymphoid malignancies, preliminary
experiments from our group using chromogenic immunohisto-
chemistry detected low levels of Cx43 protein in formalin fixed-
paraffin embedded samples from 4 non-tumor lymph nodes and
absence of signal in a set of 22 malignant B cell lymphomas
(13 Diffuse large B cell lymphomas [DLBCL] and 9 classical
Hodgkin lymphomas [CHL]) (Figure 3). While distinctive Cx43-
positive plaques were evident toward the intercalated discs of
human myocardiocytes used as positive control (Figures 3A,B),
only focal labeling of Cx43 in occasional germinal centers from
reactive-type lymph nodes was seen in cells with morphol-
ogy consistent with endothelial cells, macrophages and follicular
dendritic cells (Figures 3C,D). The latter finding is somewhat
consistent with previous observations by Krenacs and collabo-
rators (Krenacs et al., 1997) and points to the possibility that
Cx43 expression in lymphocytes might be too low to be detected
by immunohistochemistry in unstimulated lymph nodes (e.g.,
lower than in myocardium). Alternatively, other Cxs known to
be present in lymphocytes such as Cx40 (Oviedo-Orta et al.,
2001) or Panxs could represent the main hemichannel form-
ing pool in native human lymphoid tissues and lymphomas. Of
note, Panx1 hemichannels have been previously shown to be
expressed in T lymphocytes and to allow the passage of ATP that
is structurally related with NAD+ and has a similar molecular
mass (MW NAD+ = 663.42 vs. ATP = 551.14) (Woehrle et al.,
2010). In addition, we found membranous-like Panx1 expression
in samples from high grade, DLBCL that showed prominent co-
localization with the pan-B cell marker CD20 in confocal stacks
(Shoji et al., unpublished observation). Future studies using more
sensitive methods and functional assays will be required to clarify
this.
The presence of hemichannels in tumor cells even without
CD38 expressionmight confer on them growth/migration advan-
tages through increased autocrine/paracrine NAD+ signaling and
the possible interaction with CD38 present in the membrane of
adjacent non-tumor cells (e.g., stromal cells). In addition, rel-
atively low increases in the extracellular NAD+ concentration
(in the micromolar range) through cell death/lysis or release
through activated hemichannels can exert local immune sup-
pressive effects through activation of ionotropic P2X7 puriner-
gic receptors in immune cells, leading to effector cytotoxic T
cell death and expansion of immune suppressive regulatory
CD4+/CD25+/FoxP3+ T cells (Tregs) (Scheuplein et al., 2009;
Hubert et al., 2010). The latter effect could favor tumor progres-
sion by shielding cancer cells from immune-mediated cell killing
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FIGURE 3 | Cx43 protein expression in human reactive lymph nodes
and lymphomas. Representative microphotographs from formalin fixed
paraffin embedded samples of morphologically normal human myocardium
(n = 3, A,B), reactive lymph node with follicular and parafollicular
hyperplasia (n = 4, C,D), diffuse large B cell lymphomas (n = 13 DLBCL,
E,F) and classical Hodgkin’s lymphoma (n = 9 CHL, G,H). Samples were
included in a tissue microarray and stained with chromogenic
immunohistochemical method for Cx43 using a mouse monoclonal
antibody at 1:100 dilution (Zymed Laboratories). Preparations were
counterstained with hematoxylin to visualize nuclei. Right panels (B,D,F,H)
show magnified insets from low power images on the left (A,C,E,G). (A,B)
Depicts control Cx43 distribution in intercalated discs of human
myocardiocytes. In non-tumor lymph nodes (C,D) Cx43 staining was
predominantly detected in endothelial cells; and in cells with morphological
features more consistent with macrophages and follicular dendritic cells.
Cx43 was not detected in DLBCL and CHL samples (E–H). Arrow in (H)
indicates Hodgkin/Reed-Stemberg cells. Bar = 50μm.
(Figure 2). Indeed, increasing studies have found elevated Cx43
and/or Cx26 to be associated with more aggressive (e.g., shorter
survival) and disseminated disease in diverse human malignan-
cies and in vitro cancer models (Kanczuga-Koda et al., 2006; Tate
et al., 2006; Naoi et al., 2007; Kyo et al., 2008; Cronier et al.,
2009; Bui et al., 2011; Lamiche et al., 2012; Stoletov et al., 2013;
Tang et al., 2013; Ghosh et al., 2014). In addition, a recent study
demonstrated that increased post-treatment Cx43 levels were sig-
nificantly associated with response to neoadjuvant chemotherapy
in human breast carcinomas (Teleki et al., 2013) and high tumor
Cx43 expression by immunohistochemistry was predictive of
response to platinum-based chemotherapy in non-small cell lung
cancer (Du et al., 2013). Notably, many of these studies reported
predominant cytoplasmic location of Cxs and failed to detect a
corresponding increase in the intercellular gap junctional com-
munication. Recently available antibodies capable of selectively
detecting (and blocking) Cx hemichannels through recognition
of extracellular loop sequences (Riquelme et al., 2013a) might
shed light on the relative contribution of hemichannels and
intercellular channels in these responses.
HEMICHANNELS IN ATP RELEASE AND PURINERGIC SIGNALING
ATP is responsible for energy storage and transfer in the form of
renewable high-energy phosphoryl bonds. In addition to its role
in cell metabolism, intracellular ATP participates in the mainte-
nance of electrochemical gradients through the fueling of pumps,
active vesicular transport and also serves as a coenzyme and
mediator for signal transduction and DNA synthesis. The cellular
levels of ATP are determined by its constant production occurring
mostly through oxidation of a variety of carbon-based substrates
(e.g., aerobic cellular respiration); and degradation by hydrolysis
into the lower level nucleotide phosphoforms ADP and AMP.
In addition to the prominent intracellular function, extracel-
lular ATP serves as a pleiotropic intercellular messenger through
its interaction with ionotropic (P2X1–P2X7) and metabotropic
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) P2
purinergic membrane receptors (Falzoni et al., 2013). Examples
of this include its function as neurotransmitter, proliferation
stimulating agent, pro-inflammatory mediator and signaling fac-
tor between immune cells. In particular, extracellular ATP has
been recognized to have a key role in the tumor-host interactions
(reviewed in Di Virgilio, 2012). Despite its prominent extracel-
lular role, the routes for cellular ATP release in both tumor and
non-tumor cells are not well characterized. Diverse mechanisms
have been proposed including passive transmembrane diffusion,
vesicular release/exocytosis, cellular lysis and extrusion through
specific chloride channels, ABC transporters, P2X7 receptors and
Cx/Panx hemichannels (Di Virgilio, 2012; Baroja-Mazo et al.,
2013; Falzoni et al., 2013; Orellana et al., 2013). The first direct
indication of ATP release occurring through Cx hemichannels
came from experiments showing that the propagation of Ca2+
waves in cultured astrocytes required the presence of extracellu-
lar ATP and Cxs expression, but not of functional intercellular
channels (Cotrina et al., 1998). In addition, cultured C6, HeLa
and U373 cells showed UTP-induced ATP release only after trans-
fection with Cx26, 32, or 43 and the responses were mimicked
by removal of extracellular Ca2+ (Cotrina et al., 1998). Later on,
numerous studies confirmed the permeability of Cx hemichan-
nels to ATP in diverse cell types and using an extensive repertoire
of experimental conditions including the removal of extracellu-
lar divalents (Arcuino et al., 2002; Stout et al., 2002; Stout and
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Charles, 2003; Gomes et al., 2005; Pearson et al., 2005; Zhao
et al., 2005; Bahima et al., 2006), mechanical stimulation (Arcuino
et al., 2002; Stout et al., 2002; Gomes et al., 2005; Zhao et al.,
2005; Richter et al., 2014), increased [Ca2+]i (Braet et al., 2003a,b;
De Vuyst et al., 2009), hypoxia/ischemic like conditions (Faigle
et al., 2008; Clarke et al., 2009), membrane depolarization (Kang
et al., 2008; Nualart-Marti et al., 2013), application of bacterial
lypopolysaccharide (De Vuyst et al., 2007), treatment with amy-
loid beta peptide (Orellana et al., 2011), exposure to hypotonic
stress (Lu et al., 2012), after spinal cord injury (Huang et al.,
2012), in activated polymorphonuclear granulocytes (Eltzschig
et al., 2006), induced by gamma irradiation (Ohshima et al., 2012)
and after air-stimulation of cultured keratinocytes (Barr et al.,
2013). Hemichannels formed by Panx1 have also been consis-
tently shown to allow the passage of ATP in diverse cell types and
experimental models (Bao et al., 2004; Locovei et al., 2006; Huang
et al., 2007; Reigada et al., 2008; Schenk et al., 2008; Buvinic et al.,
2009; Iglesias et al., 2009; Qiu and Dahl, 2009; Ransford et al.,
2009; Chekeni et al., 2010; Garré et al., 2010; Murata et al., 2010;
Sridharan et al., 2010; Woehrle et al., 2010; Seminario-Vidal et al.,
2011; Dolmatova et al., 2012; Iglesias and Spray, 2012; Li et al.,
2012a,b; Lohman et al., 2012; Sandilos et al., 2012; Xia et al., 2012;
Xiao et al., 2012; Pinheiro et al., 2013; Riquelme et al., 2013b).
Moreover, Panx1 hemichannels are functionally coupled to P2X
and P2Y receptors activation (Locovei et al., 2006; Pelegrin and
Surprenant, 2006; Wang et al., 2013a,b).
Hemichannels, ATP release and anti-tumor immune suppression
The levels of extracellular ATP correspond to the result between
cellular release through diverse routes including hemichannels
and degradation by ectonucleotidases (e.g., CD39 and CD73).
Such enzymes mediate the extracellular conversion of ATP to
AMP (CD39) and to adenosine (CD73) that interacts with pre-
dominantly immune inhibitory adenosine receptors (e.g., A2A),
thus driving the shift from ATP driven pro-inflammatory envi-
ronment to an adenosine-driven antiinflammatory/immune sup-
pressive state (Antonioli et al., 2013) (Figure 2, red arrows and
text). The latter mechanism might represent a negative regu-
latory switch to limit the inflammatory response and control
tissue damage. However, relatively high concentrations of ATP
(milimolar range) acting on P2X and P2Y receptors can induce
marked suppressive effects in lymphocytes (Trabanelli et al., 2012;
Burnstock and Di Virgilio, 2013). Consequently, increased extra-
cellular ATP can potentially favor or suppress the local anti-tumor
immune response, depending on its concentration, the presence
and relative abundance of adenosine and P2 receptors in tumor
and inflammatory cells, and the rate of conversion to adenosine
by nucleotidases (Di Virgilio, 2012). In general, tumor microen-
vironments are considered to be purine-rich and CD39 and CD73
are commonly upregulated by hypoxia in diverse cancers leading
to a more immune-suppressive tumor niche (Di Virgilio, 2012;
Ghiringhelli et al., 2012; Antonioli et al., 2013). Consistent with
this notion, expression of CD39 and CD73 are associated with
more aggressive and metastatic tumors. The recent emergence of
immunostimulatory drugs blocking immune inhibitory check-
point pathways such as CTLA-4 and the PD-1/PD-L1 axis have
shown unprecedented prominent and lasting clinical responses
in patients with advanced solid tumors (Quezada and Peggs,
2013). Therefore, it is not surprising that strategies to inhibit
CD39 and CD73 in cancer patients are being actively pursued.
Unfortunately, most available in vitro and animal models to study
the role of hemichannels in cancer cells are not helpful in eval-
uating their possible effect in the anti-tumor immune response
(e.g., monocultures and immune defficient animals). Future stud-
ies using reconstituted cell culture systems including tumor cells
and lymphocytes/APCs or immunocompetent animalmodels will
help clarifying this issue.
Hemichannels, ATP release and cell proliferation
In addition to the inflammatory/immune effect, it has long been
known that nucleotides have direct actions on tumor cells and
most human neoplasms express a wide variety of purinergic
receptors (Stagg and Smyth, 2010; Roger and Pelegrin, 2011;
Burnstock and Di Virgilio, 2013). The effect of extracellular
ATP in tumor cell proliferation/survival is complex and appar-
ently depends on the ATP concentration, secretion pattern and
the reportoir of purinergic receptors available in the target cell
(Burnstock and Di Virgilio, 2013). Moreover, activation of the
same receptor can induce apoptosis or even increase cell prolif-
eration in different cell types. Extracellular nucleotides have been
shown to induce anti-cancer effect in diverse tumor types and
strategies to exploit this effect using ATP infusions or synthetic
ATP analogs are ongoing. However, it is also clear that low doses
of ATP as seen during spontaneous release from cells can have a
pro-proliferative and growth promoting effect (Di Virgilio, 2012;
Burnstock andDi Virgilio, 2013). In general, tumor cells have very
high ATP content compared with non-tumor cells and strategies
to reduce ATP have also been shown to enhance the activity of
anti-cancer agents (Burnstock and Di Virgilio, 2013).
One of the most studied, yet still controversial P2 receptor in
cancer cells is the so-called cytolytic P2X7 receptor. Although rela-
tively high (millimolar range) concentrations of extracellular ATP
can induce cell death through P2X7 receptor activation, more typ-
ically secreted (micromolar range) ATP concentrations are associ-
ated with promotion of cell survival/growth (Roger and Pelegrin,
2011; Di Virgilio, 2012). In support of this notion, expression of
P2X7 receptor in some tumor models is associated with increased
growth rate and metastases (Stagg and Smyth, 2010; Roger and
Pelegrin, 2011; Di Virgilio, 2012). Also, signaling through some
P2Y receptors such as P2Y2 has been associated with increased
cell survival, proliferation and migration (White and Burnstock,
2006; Stagg and Smyth, 2010; Burnstock and Di Virgilio, 2013). In
addition, it was recently shown that ATP released by non-tumor
osteocytic cells treated with alendronate can either inhibit or
stimulate the cell growth and migration of cultured MDA-MB231
breast cancer cell lines depending on the extracellular ATP con-
centration present (Zhou et al., 2014). While the inhibitory effect
was seen with relatively low ATP concentrations and required
P2X7 expression/activation; higher extracellular ATP levels were
associated with increased tumor cell migration that was medi-
ated by adenosine signaling through the A2A receptor. Similar
observations were made in MDA-MB231 mouse xenographs,
confirming the importance of this mechanism in vivo. Taken
together, this indicates that both the release of ATP by adjecent
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non-tumor cells and the rate of conversion to adenosine par-
ticipate in the ATP-mediated tumor cell proliferative responses.
The biphasic effect of extracellular ATP could partially explain
the dissimilar impact of ATP signaling in cell proliferation and
survival seen in different models (Figure 2). Moreover, it sug-
gests that treatment with non-hydrolizable forms of ATP could
have prominent anti-cancer effects by limiting its conversion to
pro-tumorigenic and immune supressive adenosine.
Notably, ATP release through activated Cx-hemichannels has
been detected after stimulation with growth factors including
nerve growth factor (NGF) (Belliveau et al., 2006); basic fibroblast
growth factor (FGF-2) (De Vuyst et al., 2007) and acidic fibrob-
last growth factor (FGF-1) (Garré et al., 2010). NGF signaling has
been implicated in diverse human malignancies (Molloy et al.,
2011). In particular, NGF and its receptors are prominent onco-
genic mediators in invasive human breast carcinomas and their
expression in malignant cells is associated with adverse patient
outcome (Dollé et al., 2004; Noh et al., 2013). Moreover, blockade
of NGF signaling using monoclonal antibodies or reducing NGF
expression with siRNA attenuates the proliferation and angio-
genesis in MDA-MB-231 cells mouse xenografts (Adriaenssens
et al., 2008). Aberrant FGFs signaling is also directly impli-
cated in developmental tissue growth and in the progression
of diverse human neoplasms and the genes encoding the four
major FGF receptors are frequently amplified and/or mutated
in human cancers (Dieci et al., 2013; Dienstmann et al., 2014).
Research is ongoing to identify effective strategies to block FGF
signaling using small molecule inhibitors and monoclonal anti-
bodies to achieve anti-tumor effect with acceptable toxicity/safety
profile. The aforementioned observations suggest that increased
hemichannel activation possibly induced by excessive growth fac-
tors signaling could favor tumor cell proliferation and expansion.
Supporting this possibility, Cx43 hemichannels were shown to
mediate the proliferation of neural progenitor cells from the ven-
tricular zone and the retinal epithelium through release of ATP,
paracrine activation of purinergic P2Y receptors and subsequent
[Ca2+]i transients (Weissman et al., 2004; Pearson et al., 2005).
In addition, two naturally occurring mutations in the human
Cx30 gene (G11R and A88V) associated with a hyperprolifer-
ative keratinocytic genodermatosis termed hidrotic ectodermal
dysplasia (or Clouston syndrome) have been demonstrated to
produce defective Cx30 hemichannels with increased ATP release
(Essenfelder et al., 2004). Although not directly measuring ATP,
blockade of Cx43 hemichannels using the Gap26 mimetic pep-
tide or carbenoxolone reduced the neointimal formation after
vascular injury through decreased proliferation of smooth mus-
cle cells (Song et al., 2009) and opening of Cx43 hemichan-
nels mediated the survival signals induced by alendronate in
osteocytic/osteoblastic cells through a Src-MAP kinases transduc-
tion dependent mechanism (Plotkin et al., 2002). The possible
involvement of increased extracellular adenosine signaling in
these responses has not been studied.
Similar to Cx hemichannels, ATP release through Panx1
hemichannels has been associated with increased prolifera-
tion of stem cells, neural progenitors (Wicki-Stordeur et al.,
2012) and primary human cultured fibroblasts stimulated with
histamine (Pinheiro et al., 2013). In the latter model, P2Y1
receptor-dependent [Ca2+]i transients were triggered by Panx1-
mediated ATP release. The release of ATP through activated Panx1
hemichannels was also shown to accelerate the assembly of mul-
ticellular C6 tumor cells aggregates in a 3D culture system (Bao
et al., 2012). The latter effect wasmediated by P2X7 receptors acti-
vation and remodeling of the F-actin cytoskeleton, and ultimately
suggests that Panx1 could particiapte in tumor cell motility.
Consistent with a pro-tumorigenic effect, Panx1 (but not other
Panxs) was found at relatively high levels in the melanoma cell
lines B16 and was associated with membranous-like location
and increased hemichannel function (Peñuela et al., 2012). In
this model, down regulation of Panx1 using siRNAs significantly
reduced the expression of the malignant melanoma markers
vimentin, hsp70 and B-catenin, and diminished the cell den-
sity and motility, but increased melanin production suggesting
acquisition of a more differentiated phenotype. Moreover, Panx1
silencing reduced the tumor size and the frequency of liver metas-
tases in a chicken embryo tumor implantation model, suggesting
that Panx1 hemichannels favor melanoma growth and progres-
sion (Peñuela et al., 2012). Similarly, silencing of Panx2 induced
the acquisition of a more differentiated neuronal-like phenotype
in N2A neuroblastoma cells (Swayne et al., 2010). Therefore, it
would not be surprising to find specific tumor types that use
hemichannels mediated mechanisms for their growth and dis-
semination. Also, the presence of subpopulations of cells with
activated hemichannels, and clones with closed hemichannels or
even lacking hemichannels in their membranes within a given
tumor is possible. Dynamic adaptations of tumor cells to envi-
ronmental pressure could also support the opportunistic transit
between the functional states of hemichannels in tumor cells (e.g.,
proliferation vs. migration or invasion).
Anti-tumor effects of ATP release through hemichannels
Although a good deal of evidence points to the possible pro-
tumorigenic and proliferative effect of both Cx and Panx1
hemichannels activation, it is relevant to consider that associ-
ation with reduced cell proliferation/survival is also apparent.
Moreover, sustained or de-regulated opening of hemichannels
can be deleterious for cells. In fact, activation of Cx43 or Panx1
hemichannels by noxious stimuli such as ischemic-like conditions
or oxidative stress can accelerate self and paracrine cell death
through massive ATP-release and [Ca2+]i-related mechanisms
(Contreras et al., 2004; Retamal et al., 2007b; Decrock et al., 2011;
Carette et al., 2014) (Figure 2). Consistent with an anti-tumor
effect, exogenous Panx1 expression was associated with decreased
proliferation, motility and anchorage-independent growth in
cultured C6 glioma cells (Lai et al., 2007). Similar findings
were obtained after expression of Panx2 (Lai et al., 2009). In
addition, Panx1 and Panx2 expression were associated with
reduced tumor volume in murine C6 tumor implants, which
led to propose them as tumor suppressor genes. In line with this
observation, forced expression of Panx1 and Panx3 increased
the dye uptake and reduced the proliferation of cultured rat
epidermal keratinocytes (Celetti et al., 2010). Data from our
group revealed that exogenous Panx1 expression significantly
reduced the cell density of cultured HeLa cells (Figure 4A). In
addition and using a previously reported antibody (Buvinic et al.,
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FIGURE 4 | (A) Exogenous Panx1 expression reduces cell density in cultured
HeLa cells. Microphotograph showing phase contrast (upper panel) and
fluorescence images (lower panel) of cultured parental HeLa cells (left) and
HeLa cells stably expressing Panx1-YFP (right, green channel 530 nm). Graph
showing the cell density of parental (boxes) and Panx1-expressing HeLa cells
(triangles) at different days of culture. Cells were exposed to 10% fetal bovine
serum and counted each 24 h for 7 days. Mean ± s.e.m. of 6 independent
experiments is shown. Bar = 30μM. (B) Panx1 expression is lower in
gallbladder adenocarcinomas. Upper-left panel: Immunohistochemical Panx1
expression using a previously reported antibody (Buvinic et al., 2009) in
morphologically normal gallbladder showing positivity in epithelial cells
(arrows) and mononuclear inflammatory cells from the lamina propria
(arrowheads). Upper-right panel: Panx1 expression in gallbladder
adenocarcinoma showing lower Panx1 expression in tumor cells. Lower
panels: Panx1 expression (left) and signal intensity (right) in normal
gallbladders, chronic cholecystitis, and gallbladder adenocarcinomas. The
amount of positive cells is expressed as percentage ± s.e.m. Intensity is
expressed as arbitrary levels (1: weak; 2: moderate; 3: strong). Experimental
conditions remained the same in all experiments. The number of cases in
each category is indicated within the bars. Bar = 25μm (C) Panx1 expression
is inversely related with proliferation in gallbladder carcinomas.
Representative microphotographs showing immunohistochemical Panx1
signal (upper panels) and Ki67 nuclear staining (lower panels, arrows) in
normal gallbladder (left) and in gallbladder adenocarcinoma (right). Graph
showing the Ki67 index in normal samples (black boxes) and in carcinomas
(triangles). Linear regression analysis showing inverse relationship between
Panx1 and Ki67 positivity in gallbladder carcinomas. R2 = 0.48; ∗p < 0.05 and
∗∗p < 0.01. Bar = 400μm.
2009), we found that Panx1 is present in morphologically normal
human gallbladder epithelium and its levels are lower in gallblad-
der adenocarcinomas (Figure 4B). Also, in gallbladder tumors
Panx1 signal is inversely related to the proliferative activity as
determined by the nuclear Ki-67 positivity rate (Figure 4C). Of
note, the rate of nuclear Ki-67 positive cells is frequently used
as a metric of the tumor proliferation grade and has prognostic
value in diverse human malignancies such as gliomas, breast
carcinomas and melanomas (Weigel and Dowsett, 2010).
The apparent discordances between the effects of Panx1
expression in proliferation and motility of melanoma, glioma
and epithelial tumor cells could be due to tumor cell-specific
and/or cell lineage-specific functions of hemichannels. Distinct
alterations in oncogenic pathways between melanocytic, glial and
epithelial tumors are well known.
HEMICHANNELS IN INTRACELLULAR CA2+ BALANCE, CELL SURVIVAL
AND MIGRATION
Intracellular Ca2+ is recognized as key second messenger and
master regulator of cell fate. Altered cytosolic Ca2+ can be asso-
ciated with cell death and cell proliferation, depending on the
cell type, concentration and biological context. The intracellu-
lar Ca2+ balance is tightly regulated and active mechanisms have
evolved to keep its levels in the low nanomolar range under
resting conditions. The extracellular levels of Ca2+ are several
orders of magnitude higher (e.g., milimolar range), creating a
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prominent inward concentration gradient. A complex signal-
ing system administrates dynamic intracellular Ca2+ reservoirs
within organelles such as the endoplasmic reticulum, mainly
through the function of endomembranous ion channels, Ca2+
ATPases and binding to Ca2+ rich proteins (Berridge et al.,
2003). Also, this system allows the functional coupling between
intracellular Ca2+ stores and extracellular signals through acti-
vation of plasma membrane receptors. Such surface receptors
include the dimeric tyrosine kinase growth factor-type recep-
tors (e.g., EGFR, FGFR, PDGFR, etc.) and a wide array of
seven-transmembrane domain G-protein coupled receptors (e.g.,
P2Y purinergic receptors, peptide hormone receptors, chemokine
receptors, neurotransmitters, etc.). In addition, the influx of Ca2+
through ligand-activated channels also participates in the intra-
cellular Ca2+ homeostasis. Intracellular Ca2+ signaling and the
generation of intercellular Ca2+ waves have been involved in key
cancer-related process including escape from apoptosis, perpet-
uation of growth, cell migration, metastasis and promotion of
angiogenesis (Monteith et al., 2007; Parkash and Asotra, 2010;
Monteith et al., 2012). In particular, Ca2+ increases have been
shown to favor cell proliferation through altered transcription
and enhance cell motility through remodeling of actin cytoskele-
ton and focal adhesions (Lee et al., 2011; Monteith et al., 2012).
Moreover, remodeling of Ca2+ signaling is a feature of diverse
cancers and consists frequently in altered expression and func-
tion of Ca2+ channels and pumps (Roderick and Cook, 2008;
Monteith et al., 2012). For instance, purinergic receptors, TRP
channels, store operated Ca2+ channels (e.g., ORAI and STIM)
and Ca2+ pumps are deregulated in diverse human tumors (Lee
et al., 2011; Chen et al., 2013). Intracellular effectors commonly
involved in the pro-oncogenic effects of Ca2+ include protein
kinases (e.g., PKC), phosphatases (e.g., calcineurin), transcription
factors (e.g., NFAT) and Ca2+-sensitive signaling proteins (e.g.,
calmodulin).
As discussed, the activation of hemichannels is linked to the
intracellular Ca2+ balance by mediating the autocrine/paracrine
signaling through transmembrane exchange of nucleotides and
Ca2+-modifying second messengers (reviewed in Wang et al.,
2013a,b) (Figure 2, blue arrows and text). In addition, early
observations suggested that hemichannels activated by metabolic
inhibition induced massive Na+ and Ca2+ entry in cultured
rabbit myocardiocytes (Li et al., 2001). In support of this
notion, recent data using reconstituted systems support that
hemichannels formed by Cx26 (Fiori et al., 2012), Cx32 (Sánchez
et al., 2009) and Cx43 (Schalper et al., 2010) allow Ca2+
influx (reviewed in Orellana et al., 2012). Notably, increasing
the [Ca2+]i with endogenous ligands (e.g., FGFs) or a Ca2+
ionophore enhances the activation of hemichannels formed by
Cx32 and Cx43 (De Vuyst et al., 2006, 2009; Schalper et al.,
2008a; Garré et al., 2010). Also, autocrine/paracrine signaling
by additional (non-nucleotide) hemichannels permeants such as
IP3, glutamate and prostaglandins involve increased intracellu-
lar Ca2+ (Schwartz and Alford, 2000; Meves, 2006; Gossman and
Zhao, 2008; Traynelis et al., 2010), suggesting the possibility of
hemichannels-mediated Ca2+ influx/Ca2+-increase/Ca2+ influx
loops (see Figure 2). To our knowledge, Panx hemichannels have
not yet been proven to be Ca2+ permeable. However, they can
also be activated by increased [Ca2+]i and the permeability prop-
erties of Panx1 hemichannels suggest that they are likely to allow
the passage of ions. Taken together, these data suggest that under
specific pro-tumorigenic circumstances (e.g., altered signal trans-
duction and tissue microenvironment) activated hemichannels
could favor cancer progression by directly increasing intracellular
Ca2+-dependent tumor cell proliferation and motility.
CONCLUSIONS AND FUTURE PERSPECTIVES
Cxs and Panxs are frequently altered in human tumors and cell
lines. Emerging data has challenged the notion that these proteins
are tumor suppressors and suggest that they could favor tumor
growth and dissemination in some circumstances. Although
diverse technical aspects limit the study of hemichannels, current
data support their involvement in the modulation of cell prolifer-
ation and migration. The presence, regulation and characteristics
of hemichannel functions in cancer cells remain largely unex-
plored, but their permeability to nucleotides and Ca2+ suggest
a possible role in favoring tumor growth and disease progres-
sion. Future efforts to characterize the expression and specific
functions of hemichannels in diverse human malignancies will
support their use as prognostic/predictive markers and to design
novel anti-cancer therapeutic strategies.
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